|
1
|
Ward E, DeSantis C, Robbins A, Kohler B
and Jemal A: Childhood and adolescent cancer statistics, 2014. CA
Cancer J Clin. 64:83–103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schwab CJ, Chilton L, Morrison H, Jones L,
Al-Shehhi H, Erhorn A, Russell LJ, Moorman AV and Harrison CJ:
Genes commonly deleted in childhood B-cell precursor acute
lymphoblastic leukemia: Association with cytogenetics and clinical
features. Haematologica. 98:1081–1088. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Den Boer ML, van Slegtenhorst M, De
Menezes RX, Cheok MH, Buijs-Gladdines JG, Peters ST, Van Zutven LJ,
Beverloo HB, Van der Spek PJ, Escherich G, et al: A subtype of
childhood acute lymphoblastic leukaemia with poor treatment
outcome: A genome-wide classification study. Lancet Oncol.
10:125–134. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mullighan CG: The genomic landscape of
acute lymphoblastic leukemia in children and young adults.
Hematology Am Soc Hematol Educ Program. 2014:174–180.
2014.PubMed/NCBI
|
|
5
|
Figueroa ME, Chen SC, Andersson AK,
Phillips LA, Li Y, Sotzen J, Kundu M, Downing JR, Melnick A and
Mullighan CG: Integrated genetic and epigenetic analysis of
childhood acute lymphoblastic leukemia. J Clin Invest.
123:3099–3111. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yoshida T, Landhuis E, Dose M, Hazan I,
Zhang J, Naito T, Jackson AF, Wu J, Perotti EA, Kaufmann C, et al:
Transcriptional regulation of the Ikzf1 locus. Blood.
122:3149–3159. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Mavrakis KJ, Van Der Meulen J, Wolfe AL,
Liu X, Mets E, Taghon T, Khan AA, Setty M, Rondou P, Vandenberghe
P, et al: A cooperative microRNA-tumor suppressor gene network in
acute T-cell lymphoblastic leukemia (T-ALL). Nat Genet. 43:673–678.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Baer C, Claus R and Plass C: Genome-wide
epigenetic regulation of miRNAs in cancer. Cancer Res. 73:473–477.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Calin GA and Croce CM: Investigation of
microRNA alterations in leukemias and lymphomas. Methods Enzymol.
427:193–213. 2007.PubMed/NCBI
|
|
12
|
Schotte D, De Menezes RX, Akbari Moqadam
F, Khankahdani LM, Lange-Turenhout E, Chen C, Pieters R and Den
Boer ML: MicroRNA characterize genetic diversity and drug
resistance in pediatric acute lymphoblastic leukemia.
Haematologica. 96:703–711. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brennecke J, Stark A, Russell RB and Cohen
SM: Principles of microRNA-target recognition. PLoS Biol.
3:e852005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xie B, Ding Q, Han H and Wu D: miRCancer:
A microRNA-cancer association database constructed by text mining
on literature. Bioinformatics. 29:638–644. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Dweep H, Sticht C, Pandey P and Gretz N:
miRWalk-database: Prediction of possible miRNA binding sites by
‘walking’ the genes of three genomes. J Biomed Inform. 44:839–847.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chou CH, Chang NW, Shrestha S, Hsu SD, Lin
YL, Lee WH, Yang CD, Hong HC, Wei TY, Tu SJ, et al: miRTarBase
2016: Updates to the experimentally validated miRNA-target
interactions database. Nucleic Acids Res. 44:D239–D247. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Betel D, Wilson M, Gabow A, Marks DS and
Sander C: The microRNA.org resource: Targets and expression.
Nucleic Acids Res. 36:D149–D153. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Betel D, Koppal A, Agius P, Sander C and
Leslie C: Comprehensive modeling of microRNA targets predicts
functional non-conserved and non-canonical sites. Genome Biol.
11:R902010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Campbell M, Castillo L, Janic D, Jazbec J,
Kaiserova E, Konja J, Kovas G, Kowalczyk J and Soycan LY: ALL
IC-BFM 2009 - A Randomized Trial of the I-BFM-SG for the Management
of Childhood non-B Acute Lymphoblastic Leukemia. Final Version of
Therapy Protocol from August-14-2009. http://tphd.org.tr/5th_hematoloji_sempozyumu/Lebriz_Yuksel_ALLIC_BFM_2009
|
|
20
|
van Dongen JJ, Lhermitte L, Böttcher S,
Almeida J, van der Velden VH, Flores-Montero J, Rawstron A, Asnafi
V, Lécrevisse Q, Lucio P, et al: EuroFlow antibody panels for
standardized n-dimensional flow cytometric immunophenotyping of
normal, reactive and malignant leukocytes. Leukemia. 26:1908–1975.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2-(Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schwickert TA, Tagoh H, Gültekin S, Dakic
A, Axelsson E, Minnich M, Ebert A, Werner B, Roth M, Cimmino L, et
al: Stage-specific control of early B cell development by the
transcription factor Ikaros. Nat Immunol. 15:283–293. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ferreirós-Vidal I, Carroll T, Taylor B,
Terry A, Liang Z, Bruno L, Dharmalingam G, Khadayate S, Cobb BS,
Smale ST, et al: Genome-wide identification of Ikaros targets
elucidates its contribution to mouse B-cell lineage specification
and pre-B-cell differentiation. Blood. 121:1769–1782. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mullighan CG, Su X, Zhang J, Radtke I,
Phillips LA, Miller CB, Ma J, Liu W, Cheng C, Schulman BA, et al:
Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N
Engl J Med. 360:470–480. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dörge P, Meissner B, Zimmermann M, Möricke
A, Schrauder A, Bouquin JP, Schewe D, Harbott J, Teigler-Schlegel
A, Ratei R, et al: IKZF1 deletion is an independent predictor of
outcome in pediatric acute lymphoblastic leukemia treated according
to the ALL-BFM 2000 protocol. Haematologica. 98:428–432. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhu YD, Wang L, Sun C, Fan L, Zhu DX, Fang
C, Wang YH, Zou ZJ, Zhang SJ, Li JY and Xu W: Distinctive microRNA
signature is associated with the diagnosis and prognosis of acute
leukemia. Med Oncol. 29:2323–2331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mi S, Lu J, Sun M, Li Z, Zhang H, Neilly
MB, Wang Y, Qian Z, Jin J, Zhang Y, et al: MicroRNA expression
signatures accurately discriminate acute lymphoblastic leukemia
from acute myeloid leukemia. Proc Natl Acad Sci USA.
104:19971–19976. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
de Oliveira JC, Scrideli CA, Brassesco MS,
Morales AG, Pezuk JA, Queiroz Rde P, Yunes JA, Brandalise SR and
Tone LG: Differential miRNA expression in childhood acute
lymphoblastic leukemia and association with clinical and biological
features. Leuk Res. 36:293–298. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhang H, Luo XQ, Zhang P, Huang LB, Zheng
YS, Wu J, Zhou H, Qu LH, Xu L and Chen YQ: MicroRNA patterns
associated with clinical prognostic parameters and CNS relapse
prediction in pediatric acute leukemia. PLoS One. 4:e78262009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Li Z, He C, Wang D, Yuan X, Chen J
and Jin J: MicroRNAs expression signatures are associated with
lineage and survival in acute leukemias. Blood Cells Mol Dis.
44:191–197. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang LC, Swat W, Fujiwara Y, Davidson L,
Visvader J, Kuo F, Alt FW, Gilliland DG, Golub TR and Orkin SH: The
TEL/ETV6 gene is required specifically for hematopoiesis in the
bone marrow. Genes Dev. 12:2392–2402. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
de Oliveira JC, Scrideli CA, Brassesco MS,
Yunes JA, Brandalise SR and Tone LG: MiR-708-5p is differentially
expressed in childhood acute lymphoblastic leukemia but not
strongly associated to clinical features. Pediatr Blood Cancer.
62:177–178. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Han BW, Feng DD, Li ZG, Luo XQ, Zhang H,
Li XJ, Zhang XJ, Zheng LL, Zeng CW, Lin KY, et al: A set of miRNAs
that involve in the pathways of drug resistance and leukemic
stem-cell differentiation is associated with the risk of relapse
and glucocorticoid response in childhood ALL. Hum Mol Genet.
20:4903–4915. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Schotte D, Chau JC, Sylvester G, Liu G,
Chen C, van der Velden VH, Broekhuis MJ, Peters TC, Pieters R and
den Boer ML: Identification of new microRNA genes and aberrant
microRNA profiles in childhood acute lymphoblastic leukemia.
Leukemia. 23:313–322. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Li X, Li D, Zhuang Y, Shi Q, Wei W and Ju
X: Overexpression of miR-708 and its targets in the childhood
common precursor B-cell ALL. Pediatr Blood Cancer. 60:2060–2067.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rane JK, Ylipää A, Adamson R, Mann VM,
Simms MS, Collins AT, Visakorpi T, Nykter M and Maitland NJ:
Construction of therapeutically relevant human prostate epithelial
fate map by utilising miRNA and mRNA microarray expression data. Br
J Cancer. 113:611–615. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bray I, Tivnan A, Bryan K, Foley NH,
Watters KM, Tracey L, Davidoff AM and Stallings RL: MicroRNA-542-5p
as a novel tumor suppressor in neuroblastoma. Cancer Lett.
303:56–64. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Wang Y, Huang JW, Castella M, Huntsman DG
and Taniguchi T: p53 is positively regulated by miR-542-3p. Cancer
Res. 74:3218–3227. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Usvasalo A, Ninomiya S, Räty R, Hollmén J,
Saarinen-Pihkala UM, Elonen E and Knuutila S: Focal 9p instability
in hematologic neoplasias revealed by comparative genomic
hybridization and single-nucleotide polymorphism microarray
analyses. Genes. Chromosomes Cancer. 49:309–318. 2010.
|
|
41
|
Sherborne AL, Hosking FJ, Prasad RB, Kumar
R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR,
Stanulla M, Schrappe M, et al: Variation in CDKN2A at 9p21.3
influences childhood acute lymphoblastic leukemia risk. Nat Genet.
42:492–494. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
42
|
Olsson L, Albitar F, Castor A, Behrendtz
M, Biloglav A, Paulsson K and Johansson B: Cooperative genetic
changes in pediatric B-cell precursor acute lymphoblastic leukemia
with deletions or mutations of IKZF1. Genes Chromosomes Cancer.
54:315–325. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Braun M, Pastorczak A, Fendler W, Madzio
J, Tomasik B, Taha J, Bielska M, Sedek L, Szczepanski T, Matysiak
M, et al: Biallelic loss of CDKN2A is associated with poor response
to treatment in pediatric acute lymphoblastic leukemia. Leuk
Lymphoma. 18:1162–1171. 2016.
|
|
44
|
Lal A, Pan Y, Navarro F, Dykxhoorn DM,
Moreau L, Meire E, Bentwich Z, Lieberman J and Chowdhury D:
miR-24-mediated downregulation of H2AX suppresses DNA repair in
terminally differentiated blood cells. Nat Struct Mol Biol.
16:492–498. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Srivastava N, Manvati S, Srivastava A, Pal
R, Kalaiarasan P, Chattopadhyay S, Gochhait S, Dua R and Bamezai
RN: miR-24-2 controls H2AFX expression regardless of gene copy
number alteration and induces apoptosis by targeting antiapoptotic
gene BCL-2: A potential for therapeutic intervention. Breast Cancer
Res. 13:R392011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Manvati S, Mangalhara KC, Kalaiarasan P,
Srivastava N and Bamezai RN: miR-24-2 regulates genes in survival
pathway and demonstrates potential in reducing cellular viability
in combination with docetaxel. Gene. 567:217–224. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Brunner S, Herndler-Brandstetter D, Arnold
CR, Wiegers GJ, Villunger A, Hackl M, Grillari J, Moreno-Villanueva
M, Bürkle A and Grubeck-Loebenstein B: Upregulation of miR-24 is
associated with a decreased DNA damage response upon etoposide
treatment in highly differentiated CD8(+) T cells sensitizing them
to apoptotic cell death. Aging Cell. 11:579–587. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Organista-Nava J, Gómez-Gómez Y,
Illades-Aguiar B, Del Carmen Alarcón-Romero L, Saavedra-Herrera MV,
Rivera-Ramírez AB, Garzón-Barrientos VH and Leyva-Vázquez MA: High
miR-24 expression is associated with risk of relapse and poor
survival in acute leukemia. Oncol Rep. 33:1639–1649.
2015.PubMed/NCBI
|
|
49
|
Talab F, Thompson V, Allen JC, Lin K and
Slupsky JR: Characterisation of B cell receptor-induced NF-κB
activation in chronic lymphocytic leukaemia cells. Blood.
116:37652015.
|
|
50
|
Niemann CU and Wiestner A: B-cell receptor
signaling as a driver of lymphoma development and evolution. Semin
Cancer Biol. 23:410–421. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Lannutti BJ, Meadows SA, Herman SE,
Kashishian A, Steiner B, Johnson AJ, Byrd JC, Tyner JW, Loriaux MM,
Deininger M, et al: CAL-101, a p110delta selective
phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell
malignancies, inhibits PI3K signaling and cellular viability.
Blood. 117:591–594. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Byrd JC, Furman RR, Coutre SE, Flinn IW,
Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, et
al: Targeting BTK with ibrutinib in relapsed chronic lymphocytic
leukemia. N Engl J Med. 369:32–42. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Baer C, Oakes CC, Ruppert AS, Claus R,
Kim-Wanner SZ, Mertens D, Zenz T, Stilgenbauer S, Byrd JC and Plass
C: Epigenetic silencing of miR-708 enhances NF-κB signaling in
chronic lymphocytic leukemia. Int J Cancer. 137:1352–1361. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Yamagishi M, Nakano K, Miyake A, Yamochi
T, Kagami Y, Tsutsumi A, Matsuda Y, Sato-Otsubo A, Muto S,
Utsunomiya A, et al: Polycomb-mediated loss of miR-31 activates
NIK-dependent NF-κB pathway in adult T cell leukemia and other
cancers. Cancer Cell. 21:121–135. 2012. View Article : Google Scholar : PubMed/NCBI
|
